

Title (en)
AMIDINE DERIVATIVES FOR TREATING AMYLOIDOSIS

Title (de)
AMIDIN-DERIVATE ZUR BEHANDLUNG VON AMYLOIDOSE

Title (fr)
DERIVES D'AMIDINE POUR LE TRAITEMENT DES AMYLOSES

Publication
EP 1572129 A4 20070328 (EN)

Application
EP 03757414 A 20030609

Priority
• US 0317992 W 20030609
• US 38700102 P 20020607

Abstract (en)
[origin: WO03103598A2] The present invention relates to the use of amidine compounds in the treatment of amyloid related diseases. In particular, the invention relates to a method of treating or preventing an amyloid-related disease in a subject comprising administering to the subject a therapeutic amount of an amidine compound. Among the compounds for use according to the invention are those according to the following Formulae, such that, when administered, amyloid fibril formation, neurodegeneration, or cellular toxicity is reduced or inhibited. Formula I, Formula II, Formula III.

IPC 8 full level
A61K 31/155 (2006.01); **A61K 31/341** (2006.01); **A61K 31/343** (2006.01); **A61K 31/4164** (2006.01); **A61K 31/4178** (2006.01); **A61K 31/4184** (2006.01); **A61K 31/421** (2006.01); **A61P 3/10** (2006.01); **A61P 25/28** (2006.01); **C07C 257/18** (2006.01); **C07D 233/06** (2006.01); **C07D 235/24** (2006.01); **C07D 235/30** (2006.01); **C07D 263/30** (2006.01); **C07D 263/32** (2006.01); **C07D 403/12** (2006.01)

CPC (source: EP)
A61K 31/155 (2013.01); **A61K 31/341** (2013.01); **A61K 31/343** (2013.01); **A61K 31/4164** (2013.01); **A61K 31/4184** (2013.01); **A61P 1/02** (2017.12); **A61P 1/04** (2017.12); **A61P 3/10** (2017.12); **A61P 7/00** (2017.12); **A61P 9/00** (2017.12); **A61P 9/04** (2017.12); **A61P 9/10** (2017.12); **A61P 11/00** (2017.12); **A61P 13/12** (2017.12); **A61P 17/02** (2017.12); **A61P 17/04** (2017.12); **A61P 17/06** (2017.12); **A61P 19/02** (2017.12); **A61P 25/00** (2017.12); **A61P 25/02** (2017.12); **A61P 25/28** (2017.12); **A61P 27/02** (2017.12); **A61P 27/16** (2017.12); **A61P 29/00** (2017.12); **A61P 31/00** (2017.12); **A61P 31/06** (2017.12); **A61P 31/08** (2017.12); **A61P 35/00** (2017.12); **A61P 35/02** (2017.12); **A61P 37/08** (2017.12); **A61P 43/00** (2017.12); **C07C 257/18** (2013.01); **C07D 235/24** (2013.01); **C07D 235/30** (2013.01); **C07D 263/32** (2013.01); **C07D 403/12** (2013.01)

Citation (search report)
• [X] WO 0004893 A2 20000203 - UNIV NORTH CAROLINA [US], et al
• [PX] WO 03017994 A1 20030306 - NEUROCHEM INC [CA], et al
• [X] OJO B ET AL: "Synthesis and biochemical activity of novel amidine derivatives as m1 muscarinic receptor agonists", BIOORGANIC AND MEDICINAL CHEMISTRY 1996 UNITED KINGDOM, vol. 4, no. 10, 1996, pages 1605 - 1615, XP002419580, ISSN: 0968-0896
• [X] MESSER WILLIAM S JR ET AL: "Tetrahydropyrimidine derivatives display functional selectivity for M-1 muscarinic receptors in brain", DRUG DEVELOPMENT RESEARCH, vol. 40, no. 2, 1997, pages 171 - 184, XP002419581, ISSN: 0272-4391
• See references of WO 03103598A2

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

Designated extension state (EPC)
AL LT LV MK

DOCDB simple family (publication)
WO 03103598 A2 20031218; **WO 03103598 A3 20060309**; AU 2003251418 A1 20031222; CA 2488493 A1 20031218; EP 1572129 A2 20050914; EP 1572129 A4 20070328; JP 2006501160 A 20060112; NO 20040497 L 20040414

DOCDB simple family (application)
US 0317992 W 20030609; AU 2003251418 A 20030609; CA 2488493 A 20030609; EP 03757414 A 20030609; JP 2004510719 A 20030609; NO 20040497 A 20040204